Chief Financial Officer · SUTRO BIOPHARMA, INC. (STRO)

Edward Albini

A named executive officer of SUTRO BIOPHARMA in every fiscal year CompBrief holds from FY2021 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,173,250

Salary $498,750Stock awards $313,260

FY2023: $1,018,488

3rd of 4 named executive officers at Sutro Biopharma by FY2024 total.

4 named officers on file for SUTRO BIOPHARMA, FY2024

Edward Albini’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • STRO’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SUTRO BIOPHARMA’s whole pay program stands against its peers

  • SUTRO BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on STRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Edward Albini’s full pay file as a PDF — free

More than this page: up to 10 years of Edward’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Edward Albini compensation by year

SUTRO BIOPHARMA Summary Compensation Table · all 3 fiscal years held
In US dollars, as SUTRO BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2023FY2024
Salary$420,000$470,833$498,750
Bonus——$0
Stock awards$738,850$182,385$313,260
Option awards$748,500$195,769$230,330
Non-equity incentive$176,400$169,500$130,910
Pension and deferred compensation$0$0$0
All other$0—$0
Total$2,083,750$1,018,488$1,173,250

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SUTRO BIOPHARMA, INC. DEF 14A filed April 25, 2025, accession 0000950170-25-058774, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SUTRO BIOPHARMA, INC. filed document, accession 0000950170-25-058774. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.

$2.1M
$1.0M
$1.2M
FY21
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU8,750$16,100—
Option3,125—$21.11

Per the Outstanding Equity Awards at Fiscal Year-End table in SUTRO BIOPHARMA, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

7 Form 4 lines since the FY2024 proxy (filed April 25, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-05-15Exercise or conversion—24,438$0.00156,519
2025-05-15Exercise or conversion—9,125$0.00176,800
2025-05-15Exercise or conversion derivative—24,438$0.0027,312
2025-05-15Exercise or conversion derivative—11,156$0.004,594
2025-05-15Tax withholding—15,995$0.88160,805
2025-05-15Exercise or conversion derivative—9,125$0.000
2025-05-15Exercise or conversion—11,156$0.00167,675

The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

SUTRO BIOPHARMA’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
William NewellChief Executive Officer$2,332,343
Jane ChungPresident and Chief Operating Officer$1,443,360
Edward Albini · this pageChief Financial Officer$1,173,250
Hans-Peter GerberChief Scientific Officer$1,153,932

The full SUTRO BIOPHARMA compensation record

free company brief

This page is one person within SUTRO BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the SUTRO BIOPHARMA proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SUTRO BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Edward Albini's compensation dossier · One-time report. No refunds.